DiaMedica Therapeutics Inc.

NasdaqCM DMAC

DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 11.38 M

DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities is USD 11.38 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -69.10% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 36.84 M, a 734,150.61% change year over year.
DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -5.02 K, a 43.57% change year over year.
DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -8.89 K, a -100.03% change year over year.
DiaMedica Therapeutics Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 28.88 M, a 94.10% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqCM: DMAC

DiaMedica Therapeutics Inc.

CEO	Mr. Dietrich John Pauls MBA
IPO Date	Aug. 3, 2012
Location	United States
Headquarters	Two Carlson Parkway
Employees	18
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Key trends

Past 5 years